Cross-Sector entity
Of the tracked stories, 4 of 5 also mention Piper Sandler, the most common co-covered peer. That works out to roughly 1.4 stories per week across a 25-day span. The busiest single day carried 3. Coverage clusters in earnings, which accounts for 3 of those 5, with the remainder spread across 2 other categories.
5 verified stories tracked
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 4 of 5 also mention Piper Sandler, the most common co-covered peer. That works out to roughly 1.4 stories per week across a 25-day span. The busiest single day carried 3. Coverage clusters in earnings, which accounts for 3 of those 5, with the remainder spread across 2 other categories. 0% of these stories carry negative sentiment. The tracked stories average 2 original sources each. This profile follows 5 Cross-Sector stories mentioning MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. across the period from July 23, 2026 to August 16, 2026.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.. Shared-story counts are live from our verified record — not editorial picks.
Quarterly earnings released
SMBC reports EPS of $1.83 vs. $1.52 estimate, revenue of $51.77M.
Piper Sandler adjusts PT
Piper Sandler reiterates Neutral, boosts target from $71 to $79.
Insider sale by EVP Windes
EVP Richard Windes sells 2,000 shares at average $69.70, totaling $139,400.
Weiss Ratings reiterates Buy
Weiss Ratings issues a 'buy (b)' rating on SMBC.
Stephens bullish call
Stephens reiterates Overweight rating, lifts PT to $76 from $72.
KBW target price increase
Keefe, Bruyette & Woods raises price target from $64 to $65, maintaining Market Perform rating.
Globant reported EPS of $1.40, missing consensus by $0.10, while revenue of $614.42 million slightly beat estimates but was flat year over year. Shares fell 8.9% to $37.35 as analysts lowered price targets. The company reiterated FY2026 EPS guidance of $5.75-$6.15 and Q3 guidance of $1.43.
Source: themarketsdaily.com · dailypolitical.com
Collegium Pharmaceutical's Q2 2026 earnings beat signals sustained demand for its abuse-deterrent pain medications. Revenue grew 6.3% to $199.88M, and EPS of $1.92 surpassed forecasts by $0.20, indicating commercial strength despite regulatory pressures.
Collegium Pharmaceutical delivered an 11.6% EPS beat and modest revenue beat, lifting shares to $29.47. High ROE and institutional accumulation offset by high leverage and mixed analyst ratings create a nuanced investment case.
Collegium Pharmaceutical's earnings beat of $0.20 per share, reaching $1.92 on $199.88M revenue, highlights its commercial success in the abuse-deterrent opioid space, a key sector for the biopharma industry.
Source: dailypolitical.com · themarketsdaily.com
Southern Missouri Bancorp delivered a strong quarter with earnings of $1.83 per share, beating estimates by $0.31 on revenue of $51.77 million. However, the stock fell 1.4% to $75.41 as analysts remain divided and insider selling raises questions.
Source: MarketBeat · tickerreport.com
